George Hicks
ACD-level Healthcare Copywriter
Professional Portfolio
Rare Disease
• Copy Director and Assistant Director of Communication for Rare Genomics Institute since 2020
• Served as lead writer on the EU-based Translarna, indicated to slow the progression of symptoms in patients with nonsense-mutation Duchenne Muscular Dystrophy
Selected Writing for Rare Genomics Institute
George has been a contributing writer for Rare Genomics Institute since 2020.
See articles >
Understanding Duchenne Muscular Dystrophy:
A Guide for Patients and their Families
Brand: Translarna
Client: PTC Therapeutics
Audience: Families of patients with Duchenne Muscular Dystrophy
Challenge: Create an easy-to-understand explanation of causes and consequences of the Duchenne Muscular Dystropy, for families and patients to facilitate daily compliance
Helping to Care for Someone with Duchenne Muscular Dystrophy: a Guide for Teachers, School Nurses, and Other Organizational Care Partners
Brand: Translarna
Client: PTC Therapeutics
Audience: Guide for school nurses and others working with patients with Duchenne Muscular Dystrophy
Challenge: Create an easy-to-understand explanation of causes and consequences of the Duchenne Muscular Dystropy, for organizational care partners for patients with Duchenne Muscular Dystrophy
Brand: Translarna
Client: PTC Therapeutics
Audience: HCPs
Challenge: Provide a real-world update to long-term data for Translarna to slow the progression of Duchenne Muscular Dystrophy reporting data from actual patients with real-world images of patients
Brand: Unbranded for Translarna
Client: Unbranded for PTC Therapeutics
Audience: Pediatric and adult neurologists who may be unfamiliar with standard of care for patients with Duchenne Muscular Dystrophy
Challenge: In a reprint carrier, provide a quick reference on standard-of-care treatment for nonsense-mutation Duchenne Muscular Dystrophy, because nmDMD is a rare variant of a rare disease so specialists may be unfamiliar with standard of care guidelines
Brand: Unbranded for Translarna
Client: Unbranded for PTC Therapeutics
Audience: Pediatric and adult neurologists who may be unfamiliar with standard of care for patients with Duchenne Muscular Dystrophy
Challenge: Emphasize the benefits of Translarna and differences between Translarna and investigational micro-dystrophin treatments for patients with nonsense mutation DMD.
Brand: Translarna
Client: PTC Therapeutics
Audience: Healthcare providers who may not be familiar with the signs and symptoms of Duchenne Muscular Dystrophy
Challenge: Translarna is most effective at slowing disease progression when treatment begins at the earliest opportunity, so this brochure was intended to build familiarity with DMD signs and symptoms
